OrbiMed’s Corvus Pharmaceuticals CRVS Stock Holding History

OrbiMed’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$105M	Hold	7,165,006	–	–	2.08%	12
2025 Q4	$55.2M	Hold	7,165,006	–	–	1.13%	27
2025 Q3	$52.8M	Hold	7,165,006	–	–	1.24%	26
2025 Q2	$28.7M	Buy	7,165,006 +221,352	+3%	+$805K	0.72%	36
2025 Q1	$22.1M	Hold	6,943,654	–	–	0.53%	41
2024 Q4	$37.1M	Hold	6,943,654	–	–	0.76%	39
2024 Q3	$36.7M	Hold	6,943,654	–	–	0.67%	43
2024 Q2	$12.6M	Hold	6,943,654	–	–	0.25%	67
2024 Q1	$12.4M	Hold	6,943,654	–	–	0.23%	76
2023 Q4	$12.2M	Hold	6,943,654	–	–	0.24%	73
2023 Q3	$10.1M	Hold	6,943,654	–	–	0.22%	85
2023 Q2	$15.9M	Hold	6,943,654	–	–	0.29%	75
2023 Q1	$6.32M	Hold	6,943,654	–	–	0.12%	98
2022 Q4	$5.9M	Hold	6,943,654	–	–	0.11%	90
2022 Q3	$5.68K	Hold	6,943,654	–	–	0.11%	103
2022 Q2	$6.88K	Hold	6,943,654	–	–	0.12%	104
2022 Q1	$11.4M	Hold	6,943,654	–	–	0.18%	94
2021 Q4	$16.7M	Hold	6,943,654	–	–	0.22%	95
2021 Q3	$33.6M	Sell	6,943,654 -1,109,644	-14%	-$3.28M	0.37%	71
2021 Q2	$21.5M	Hold	8,053,298	–	–	0.22%	95
2021 Q1	$24.8M	Buy	8,053,298 +1,285,714	+19%	+$4.64M	0.23%	89
2020 Q4	$24.1M	Hold	6,767,584	–	–	0.21%	92
2020 Q3	$27.1M	Hold	6,767,584	–	–	0.34%	76
2020 Q2	$18.4M	Hold	6,767,584	–	–	0.26%	80
2020 Q1	$14.3M	Hold	6,767,584	–	–	0.24%	79
2019 Q4	$36.8M	Hold	6,767,584	–	–	0.53%	53
2019 Q3	$20.4M	Buy	6,767,584 +201,899	+3%	+$847K	0.39%	64
2019 Q2	$24.6M	Buy	6,565,685 +598,101	+10%	+$2.34M	0.38%	61
2019 Q1	$24M	Hold	5,967,584	–	–	0.37%	65
2018 Q4	$21.9M	Hold	5,967,584	–	–	0.41%	66
2018 Q3	$51.2M	Hold	5,967,584	–	–	0.62%	49
2018 Q2	$65.5M	Hold	5,967,584	–	–	0.78%	40
2018 Q1	$68.8M	Buy	5,967,584 +588,235	+11%	+$5.56M	0.85%	40
2017 Q4	$55.7M	Hold	5,379,349	–	–	0.7%	43
2017 Q3	$85.7M	Hold	5,379,349	–	–	0.82%	37
2017 Q2	$65.1M	Hold	5,379,349	–	–	0.68%	47
2017 Q1	$112M	Hold	5,379,349	–	–	1.27%	27
2016 Q4	$76.9M	Hold	5,379,349	–	–	0.98%	33
2016 Q3	$88.5M	Hold	5,379,349	–	–	1.01%	37
2016 Q2	$76.7M	Buy	5,379,349 +120,899	+2%	+$1.63M	0.8%	43
2016 Q1	$76.2M	Buy	+5,258,450	New	+$75.4M	0.8%	39

Other funds holding CRVS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

OrbiMed's CRVS Position: Q1 2026 in Review

OrbiMed held its Corvus Pharmaceuticals (CRVS) position steady in Q1 2026 at 7,165,006 shares worth $105M. The position accounts for 2.08% of the portfolio, ranked #12.

OrbiMed first reported a position in CRVS in Q1 2016 and has held it in 41 quarters since. The position peaked at $112M in Q1 2017. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

OrbiMed held 7,165,006 shares of Corvus Pharmaceuticals worth $105M as of Q1 2026.
OrbiMed left its Corvus Pharmaceuticals share count unchanged in Q1 2026.
Corvus Pharmaceuticals made up 2.08% of OrbiMed's portfolio in Q1 2026, its #12 holding.
OrbiMed first reported a position in Corvus Pharmaceuticals in Q1 2016 and has held it in 41 quarters since.
OrbiMed's Corvus Pharmaceuticals position peaked at $112M in Q1 2017.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.